{no_xhr} {include file="page/head.html" template="home"} {include file="page/navigation.html" view="default"} {/no_xhr} {include file="page/hero.html"} News {$MAIN_CONTENT_EDIT_START} {$MAIN_CONTENT} Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208) Resverlogix Files 2016 Year-End Disclosure Documents Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs Discover {no_xhr} {include file="page/footer.html"} {include file="page/tail.html"} {/no_xhr}
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
Resverlogix Files 2016 Year-End Disclosure Documents
Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs